RecruitingNCT04850053

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）

Sponsor

Capital Medical University

Enrollment

1,500 participants

Start Date

Aug 26, 2020

Study Type

OBSERVATIONAL

Conditions

Alzheimer s Disease

Summary

The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia. To perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.

Eligibility

Min Age: 55 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study aims to improve diagnosis of Alzheimer's disease and related dementias by looking for specific biological markers — tiny protein clumps called "seeds" — in body fluid samples like blood or cerebrospinal fluid. **You may be eligible if...** - You are between 55 and 75 years old - You have been diagnosed with Alzheimer's disease or another form of dementia, OR you have normal cognition (healthy volunteers) - You or your legal guardian can provide written informed consent **You may NOT be eligible if...** - You have another significant medical or psychiatric illness - You are unable to complete a cognitive test - You are unwilling to provide a biological sample Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Xuanwu Hospital of Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04850053

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216106 locations

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

NCT072349426 locations

Study on the Effect of 40 Hz Non-Invasive Light Therapy System

NCT052601771 location

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203123 locations